Why is therapy with rasagiline recommended before levodopa to start treatment in patients with Parkinson’s disease? Review article
Article Sidebar
Published:
Dec 31, 2018
Keywords:
rasagiline, Parkinson’s disease, monotherapy
Main Article Content
Abstract
Rasagiline is an irreversible, selective, second generation MAO-B inhibitor. It’s efficacy in monotherapy in early Parkinson’s disease (PD) was well established in the clinical trials, although its symptomatic effects are typically mild. Earlier initiation of rasagiline treatment is associated with improved long-term outcomes compared with delayed therapy. Recent studies have indicated that rasagiline may be neuroprotective, but the neuroproective features of rasagiline weren’t unambiguously proved. Rasagiline has a relevant place in early PD treatment.
Article Details
How to Cite
Gorzkowska, A. (2018). Why is therapy with rasagiline recommended before levodopa to start treatment in patients with Parkinson’s disease?. Medycyna Faktow (J EBM), 11(4(41), 279-282. https://doi.org/10.24292/01.MF.0418.3
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Finberg J.P., Lamensdorf I., Commissiong J.W. et al.: Pharmacology and neuroprotective properties of rasagiline. J. Neural. Transm. Suppl. 1996; 48: 95-101.
2. Bar-Am O., Amit T., Youdim M.B.: Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro. J. Neurochem. 2007; 103: 500-508.
3. Parkinson Study Group: A controlled trial of rasagiline in early Parkinson disease. The TEMPO Study. Arch. Neurol. 2002; 59: 1937-1943.
4. Masselis M., Collinson S., Freeman N. et al.: Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson’s disease: a pharmacogenetic study. Brain 2016; 139(Pt 7): 2050-2062.
5. Ferreira J.J., Katzenschlager R., Bloem B.R. et al.: Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson’s disease. Eur. J. Neurol. 2013; 20: 5-15.
6. Maruyama W., Akao Y., Carrillo M.C. et al.: Neuroprotection by propargylamines in Parkinson’s disease: suppression of apoptosis and induction of prosurvival genes. Neurotoxicol. Teratol. 2002; 24: 675-682.
7. Finberg J.P., Takeshima T., Johnston JM. et al.: Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor. Neuroreport 1998; 9: 703-707.
8. Jenner P., Langston J.W.: Explaining ADAGIO – a critical review of biological basis for the clinical effects of rasagiline. Mov. Disord. 2011; 26: 2316-2323.
9. Heikkila R.E., Duvoisin R.C., Finberg J.P. et al.: Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B. Eur. J. Pharmacol. 1985; 116: 313-317.
10. Blandini F., Armentero M.T., Fancellu R. et al.: Neuroprotective effect of rasagiline in a rodent model of Parkinson’s disease. Exp. Neurol. 2004; 187: 455-459.
11. Parkinson Study Group: A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch. Neurol. 2004; 61: 561-566.
12. Olanow C.W., Stern M.B., Sethi K.: The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology 2009; 72(21 Supl. 4): S1-136.
13. Dietrichs E., Odin P.: Algorithms for the treatment of motor problems in Parkinson’s disease. Acta Neurol. Scand. 2017; 136(5): 378-385.
14. Olanow C.W., Rascol O., Hauser R. et al.: A double-blind, delayed start trial of rasagilline in Parkinson’s disease. N. Engl. J. Med. 2009; 361(13): 1268-1278.
15. Rascol O., Fitzer-Attas C.J., Hauser R. et. al.: A double-blind, delayed-start trial of rasagiline in Parkinson’s disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol. 2011; 10(5): 415-423.
16. Jankovic J., Berkovich E., Eyal E. et al.: Symptomatic efficacy of rasagiline monotherapy in early Parkinson’s disease: post-hoc analyses from the ADAGIO trial. Parkinsonism Relat. Disord. 2014; 20(6): 640-643.
17. Rascol O., Hauser R., Stocchi F. et al.: Long-term effects of rasagilline and nat ural history of treated Parkinson’s disease. Mov. Disord. 2016; 31: 1489-1496.
18. Opala G., Gorzkowska A.: Rasagilina – nowa opcja leczenia choroby Parkinsona. Neurologica 2005; 1(13): 29-32, 40.
2. Bar-Am O., Amit T., Youdim M.B.: Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro. J. Neurochem. 2007; 103: 500-508.
3. Parkinson Study Group: A controlled trial of rasagiline in early Parkinson disease. The TEMPO Study. Arch. Neurol. 2002; 59: 1937-1943.
4. Masselis M., Collinson S., Freeman N. et al.: Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson’s disease: a pharmacogenetic study. Brain 2016; 139(Pt 7): 2050-2062.
5. Ferreira J.J., Katzenschlager R., Bloem B.R. et al.: Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson’s disease. Eur. J. Neurol. 2013; 20: 5-15.
6. Maruyama W., Akao Y., Carrillo M.C. et al.: Neuroprotection by propargylamines in Parkinson’s disease: suppression of apoptosis and induction of prosurvival genes. Neurotoxicol. Teratol. 2002; 24: 675-682.
7. Finberg J.P., Takeshima T., Johnston JM. et al.: Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor. Neuroreport 1998; 9: 703-707.
8. Jenner P., Langston J.W.: Explaining ADAGIO – a critical review of biological basis for the clinical effects of rasagiline. Mov. Disord. 2011; 26: 2316-2323.
9. Heikkila R.E., Duvoisin R.C., Finberg J.P. et al.: Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B. Eur. J. Pharmacol. 1985; 116: 313-317.
10. Blandini F., Armentero M.T., Fancellu R. et al.: Neuroprotective effect of rasagiline in a rodent model of Parkinson’s disease. Exp. Neurol. 2004; 187: 455-459.
11. Parkinson Study Group: A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch. Neurol. 2004; 61: 561-566.
12. Olanow C.W., Stern M.B., Sethi K.: The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology 2009; 72(21 Supl. 4): S1-136.
13. Dietrichs E., Odin P.: Algorithms for the treatment of motor problems in Parkinson’s disease. Acta Neurol. Scand. 2017; 136(5): 378-385.
14. Olanow C.W., Rascol O., Hauser R. et al.: A double-blind, delayed start trial of rasagilline in Parkinson’s disease. N. Engl. J. Med. 2009; 361(13): 1268-1278.
15. Rascol O., Fitzer-Attas C.J., Hauser R. et. al.: A double-blind, delayed-start trial of rasagiline in Parkinson’s disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol. 2011; 10(5): 415-423.
16. Jankovic J., Berkovich E., Eyal E. et al.: Symptomatic efficacy of rasagiline monotherapy in early Parkinson’s disease: post-hoc analyses from the ADAGIO trial. Parkinsonism Relat. Disord. 2014; 20(6): 640-643.
17. Rascol O., Hauser R., Stocchi F. et al.: Long-term effects of rasagilline and nat ural history of treated Parkinson’s disease. Mov. Disord. 2016; 31: 1489-1496.
18. Opala G., Gorzkowska A.: Rasagilina – nowa opcja leczenia choroby Parkinsona. Neurologica 2005; 1(13): 29-32, 40.